Navigation Links
Chemotherapy plus synthetic compound provides potent anti-tumor effect in pancreatic cancers
Date:3/23/2010

DALLAS March 23, 2010 Human pancreatic cancer cells dramatically regress when treated with chemotherapy in combination with a synthetic compound that mimics the action of a naturally occurring "death-promoting" protein found in cells, researchers at UT Southwestern Medical Center have found.

The research, conducted in mice, appears in today's issue of Cancer Research and could lead to more effective therapies for pancreatic and possibly other cancers, the researchers said.

"This compound enhanced the efficacy of chemotherapy and improved survival in multiple animal models of pancreatic cancer," said Dr. Rolf Brekken, associate professor of surgery and pharmacology and the study's senior author. "We now have multiple lines of evidence in animals showing that this combination is having a potent effect on pancreatic cancer, which is a devastating disease."

In this study, Dr. Brekken and his team transplanted human pancreatic tumors into mice, then allowed the tumors to grow to a significant size. They then administered a synthetic compound called JP1201 in combination with gemcitabine, a chemotherapeutic drug that is considered the standard of care for patients with pancreatic cancer. They found that the drug combination caused regression of the tumors.

"There was a 50 percent regression in tumor size during a two-week treatment of the mice," Dr. Brekken said. "We also looked at survival groups of the animals, which is often depressing in human therapeutic studies for pancreatic cancer because virtually nothing works. We found not only significant decrease in tumor size, but meaningful prolongation of life with the drug combination."

The drug combination was also effective in an aggressive model of spontaneous pancreatic cancer in mice.

The compound JP1201 was created in 2004 by UT Southwestern researchers to mimic the action of a protein called Smac. The researchers discovered Smac in 2000 and found that this protein plays a key role in the normal self-destruction process present in every cell.

Cell death, or apoptosis, is activated when a cell needs to be terminated, such as when a cell is defective or is no longer needed for normal growth and development. In cancer cells, this self-destruct mechanism is faulty and lead to breaks in the cell-death cascade of events. The synthetic Smac, or Smac mimetic, developed at UT Southwestern inhibits these breaks, allowing the cell to die.

"In essence, we're inhibiting an inhibitor," Dr. Brekken said. "And we're allowing the apoptotic cascade to kick off, resulting in the death of cancer cells."

UT Southwestern researchers are using Smac mimetics in breast and lung cancer research, as well. Dr. Brekken said the next step is to develop a compound based on JP1201 that can be tested in humans in clinical trials.


'/>"/>

Contact: Connie Piloto
connie.piloto@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Researchers find new chemotherapy combination shows promise in endometrial cancer
2. Study evaluates costs and benefits of new chemotherapy drugs
3. Scientists identify microRNA as possible cause of chemotherapy resistance
4. Roche/Genentech/Chugais Herceptin as an Add-On to Standard Chemotherapy Will Become Decision Resources Clinical Gold Standard in 2013 for the Treatment Of Gastric Cancer
5. New developments in nanotechnology tackle the 2 biggest problems associated with chemotherapy
6. Breast cancer multigene test helping patients avoid chemotherapy
7. Mayo Clinic researchers say breast cancer survival improves Herceptin used with chemotherapy
8. Criteria based on CT imaging after chemotherapy may help predict survival
9. Synthetic, dissolving plates ease repairs of nasal septum defects
10. Synthetic Platelets Put the Brakes on Blood Loss
11. Synthetic Red Blood Cells Developed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... ... , ... NCPDP Foundation , a 501(c)(3) nonprofit charitable ... $40,000 grant to Johns Hopkins Medicine to address patient safety risk by implementing ... cancel a prescription already submitted to a pharmacy. Studies indicate that up to ...
(Date:9/25/2017)... ... September 25, 2017 , ... International Water Advocate ... Sharon Kleyne Hour Power of Water, Global Climate Change and Your Health on ... focus from a once-every-four-years series of events to a personal, daily Health Olympics. ...
(Date:9/25/2017)... ... , ... Bobbie Horowitz was hardly able to walk without excruciating pain in ... and theater producer, Horowitz would manage to get to rehearsals on time, but wasn’t ... so she had to take a cab everywhere. , It wasn’t until she ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... services supporting clinical research, today announces that 30 of its domain experts ... drug development lifecycle at upcoming industry conferences and webinars. Drawing on broad ...
(Date:9/25/2017)... Port Richey, FL (PRWEB) , ... September 25, 2017 , ... ... New Port Richey, Fla. location at 5304 Main Street as an interventional pain management ... of the spine and extremities. He joins PPOA from private practice In Brooksville, Fla. ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... -- Just 18 months after its February 2016 launch, market ... appointment of three new senior people to its rapidly ... and James Wright bring decades of ... Tammy Wynne joins as Director, Value ... has over ten years, experience in global market access ...
(Date:9/1/2017)... , Sept. 1, 2017 Michael ... Solutions, Inc , highlights opportunities for growth in his ... report that Marlin Equity is seeking a buyer for ... annual award-winning 22-year-old healthcare solutions Value Added Reseller and ... "As the healthcare market ...
(Date:9/1/2017)... , Sept. 1, 2017  Bayer will present the latest ... Society for Medical Oncology (ESMO) 2017 Congress, September 8-12 in ... include new preclinical and clinical data on Bayer,s marketed portfolio ... pipeline projects. "We ... minds in cancer research at ESMO," said Carsten Brunn ...
Breaking Medicine Technology: